1007
ONKOLOGIE3418043010760120167227269329388409453
/8408043010731
Onkologie.9168043010761110147195214263313331375390
2023;17(3):150-1561326804301074487128172186223260280323344358396433476506545582626
/19978043010731
www.onkologiecs.cz48658043010765133201214262311348396415464514532576617652669709748
1561308026012657110168
HLAVNÍ341207012670127198263336370
TÉMA733207012657114204274
Specifika3413650106316597131149179197232274
léčby6313650106296196132168
HER281536501063971107142
pozitivního97136501063374105123155173211252270311352
karcinomu133836501063476111146163204245299340
prsu169336501063368103143
u1852365010639
mladých190636501065283125165200232273
pacientek219536501063370103120152194226258294
LITERATURA34158001234978134189250318368438498567
1.3407400853547
SVOD3997410833268114159
[Internet].57074108318337091124144182216238254266
[cited84874108318476283116155
20231015741083336698132
May11597410835485115
15].128674108334638293
Available13917410834170102117131163201216250
from:1653741083183976133144
https://1809741083375881120146158184203
svod.cz/.340841083265997136150182212240246
2.3409400853754
Adami4209410834282116177193
HO,6399410834595108
Malker7729410835791107139175198
B,9959410833751
Holmberg10719410834686103163204242265305
L,14019410833347
et14749410833559
al.1559941083334963
The16489410833475112
relation1785941083225774108131148188228
between34010410834077100155191228268
survival6301041083276588124141175209225
and87710410833372113
age101210410833373110
at114410410833255
diagnosis12211041083395589129169209237252280
in152310410831554
breast15991041083406298131159183
cancer.180410410833267106140175197208
N340114108345
Engl40011410833370109125
J540114108324
Med.58011410835489129142
1986;315(9):559-563.7371141083346499135147182213243261293311323358391423447481515549561
3.34012400853651
Keegan40712410833569105144176214
THM,63812410833278133146
DeRouen80012410834681117155194228267
MC,108312410835495108
Press12071241083355690117143
DJ,13661241083466880
et146212410833456
al.15341241083324861
Occurrence161112410834779110148169191225263295329
of195612410833756
breast3401341083396094126153176
cancer53213410833264103135168190
subtypes73813410832663103125158198234261
in101513410831553
adolescent108413410833271109125160187219253291312
and141313410833270109
young153813410833169107145184
adult173813410833271109124146
women.19011341083508834014410835792130144
Breast4991441083355791123149172
Cancer68714410834072110143176198
Res9001441083357097
BCR.101214410833676112127
2012;14(2):R55.115414410833468100130142172203223257275287323358391403
4.34015400853651
Tun40515410833366104
NM,522154108345100114
Villani649154108336526782114152168
G,83015410834457
Ong90015410834786125
K,103815410833550
et110115410833457
al.11711541083324760
Risk12441541083365177107
of136515410833756
having143515410833769101117155194
BRCA1164215410833571112155185
mutation1840154108357951171503401641083223775113
in47016410831452
high-risk5391641083375291129151173189215245
women80016410835189147182220
with10371641083506688126
triple-negative1180164108321435898113148171210245285317339354387421
breast16171641083396195127153176
cancer:181016410833164102134168189203
a340174108332
meta-analysis.38717410835792115148170202240273288320347362388401
Clin8041741083405570108
Genet.92717410834479117152174188
2014;85(1):43-48.113017410833468100131143178212230262276288322355377413449463
5.34018400853650
Moore40418410835493132153187
HCF,60518410834485117123
Unger74218410834482121156177
JM,9331841083247992
Phillips10391841083357388103118133172199
KA,12521841083357993
et135918410833456
al.14291841083324760
Goserelin150318410834482109144165199215230268
for17851841083185677
Ovarian1876184108347811143401941083213668105
Protection4581941083355592114147180204219256294
during7651941083387596112149188
Breast-Cancer9651941083365790122148171191233266303335369390
Adjuvant13671941083417994131164196234255
Chemotherapy.1635194108340771121692072292673013223553402041083397080
N435204108345
Engl49520410833371110125
J635204108324
Med.67520410835489129142
2015;372(10):923-932.83220410833469100130141176208243260292323341353389422456478513546579591
6.34021400853652
Zagouri40621410833871110148186207223
F,64321410833238
Sergentanis6952141083336889127162200221254292307333
TN,10422141083337992
Chrysikos11482141083407899133160175205242269
D,143121410834556
et150121410833456
al.15712141083324861
Trastuzumab16462141083324982109132170199238295328367
administration34022410833271129144182197223246267300322338375414
during7732241083387697113151190
pregnancy:9822241083396094134172204242275308322
a1323224108332
systematic13742241083265986109143201233255270302
review16962241083205487102137188
and190422410833169108
meta-analysis.34023410835792115147170202240273288320347362388401
Breast7572341083355690122149172
Cancer94423410834073111143177198
Res11572341083367198
Treat.12702341083325084116137151
2013;137(2):349-357.143623410833468100130141172201234250284302314349384417441473506540546
7.34024400853644
Dawood39724410834577127164203242
S,65224410833244
Broglio7092441083355693132147162200
K,92124410833549
Buzdar98324410833573102139171192
AU,11882441083418393
et129424410833456
al.13622441083324760
Prognosis14342441083355693132169207234248274
of172124410833756
Women178924410835793151186224
With3402541083577496134
Metastatic48825410835590112145171194227249264296
Breast7982541083365791123149173
Cancer98525410834072110143176197
by119625410833970
HER2128025410834578113149
Status14432541083325386108146172
and162925410833270109
Trastuzumab1752254108333508310913217020023834026410835790129
Treatment:4832641083324984115137195230268290303
An80026410834179
Institutional-Based8932641083155379102118140178201216254292325340362399432459494533
Review.144026410833671103119153204215
J1669264108324
Clin17072641083405570108
Oncol.182926410834785118154170183
2010;28(1):92-98.34027410833468100131144179213232264278290325358379414449462
8.34028400853652
Smith40828410833290105128166
IE.5902841083154861
Efficacy668284108332506886118151183216
and90128410833270109
safety10262841083265978113135169
of121128410833757
Herceptin128428410834479101132165205227242280
in158028410831553
women164928410835189147182220
with18852841083516789127
metastatic34029410835792114146172195227249264295
breast6482941083386093125151174
cancer:83529410833163101132166187200
results10482941083205480117132154182
from12422941083184077135
pivotal13892941083395486123145177192
clinical1594294108331466198113145177192
studies.17992941083264986125140174200214
Anticancer34030410834179101116148181219251285306
Drugs.66130410834667106145171184
2001;1286130410833468104136144174204
Suppl108030410833370109149165
4:S3-10.12603041083344680114136167198211
9.34031400853649
Dj40431410834561
S,47931410833346
B539314108335
LJ,5893141083315971
S674314108333
S,72131410833345
et78131410833456
al.8523141083324760
Use92631410834470105
of104531410833857
chemotherapy111731410833169104162200222260295316349388420
plus15513141083395592119
a1684314108332
monoclonal1731314108357951341722052202583403241083387085
antibody4403241083327092107146185225256
against71232410833170103118156182205
HER293232410834578113149
for10963241083185678
metastatic118932410835792115147174197230252267299
breast15033241083396094126153176
cancer169432410833164102134168189
that18983241083226093114
overexpresses34033410833769103125159190230251285312339374401
HER2.75633410834477113148161
N932334108345
Engl99233410833371110125
J1132334108324
Med.117233410835489129142
2001;344(11):783-792.132933410833469105137145180215252272303331345357391424458480511544578590
10.3403440085367186
Marty44734410835588110135169
M,63734410835669
Cognetti72734410834178119157193216241256
F,100434410833339
Maraninchi106434410835588110144182198236269308323
D,140834410834657
et148634410833557
al.15643441083334862
Randomized164734410833569108147186245261290325365
phase34035410833977109136171
II52635410831530
trial571354108322435991106
of69335410833756
the7643541083226095
efficacy874354108334537188121153186219
and110835410833270109
safety12323541083266078113135169
of141635410833757
trastuzumab14883541083224376102126164193231289321361
combined1864354108331681263403641083405695131172
with5333641083526892131
docetaxel68536410833979113147170204237272288
in99536410831554
patients10703641083407497113148188210239
with13303641083526892131
human148236410833978137170210
epidermal17133641083357592132168190250283299
growth3403741083385996148172210
factor5693741083185284108145166
receptor7543741083215587121160182219241
2-positive10133741083355595134160175198213246280
metastatic131137410835893115148174198230252267299
breast16293741083396094126153176
cancer182337410833264102135168190
administered34038410833170126141178193218241274294328367
as71938410833157
first-line788384108317345481103122138153190224
treatment:10243841083224276107128185219257278291
the13273841083215993
M77001143238410835486120152188219
study16633841083264885124155
group.18303841083385895132170182
J340394108324
Clin3793941083405570108
Oncol50239410834786118155171
Off6883941083476886
J789394108325
Am82939410834199
Soc94239410833371104
Clin10613941083405570108
Oncol.118439410834786118155170183
2005;23(19):4265-4274.138239410833569105139150185219237269299317329364396430464486522555588618631
11.3404040085376880
Piccart-Gebhart4424041083365184116149171197217265301342381414436462
MJ,9254041083568295
Procter10414041083365796129154189211
M,127340410835670
Leyland-Jones13644041083326799116149188228251273313352388416
B,180140410833650
et187240410833457
al.19514041083324862
Trastuzumab3404141083325082109132170199237295327366
after7194141083325176109130
adjuvant8624141083327186124156189227248
chemotherapy112341410833169104162200222260295316349388419
in155541410831452
HER2-positive162041410834477113148168208247274288311326358392
breast3404241083396094126153176
cancer.53142410833164102134168189200
N746424108345
Engl80642410833370109125
J946424108324
Med.98642410835489129142
2005;353(16):1659-1672.114342410833468104139149184217250268300331349361391422456488512543574607641654
12.3404340085366884
Slamon4414341083324880138176215
D,67243410834657
Eiermann7454341083334883104162195233271
W,103343410835767
Robert111743410833573113148170194
N,132843410834558
et140243410833457
al.14764341083314760
Adjuvant15534341083407994132164197235257
trastuzumab1827434108321437610212516334044410832970130165206
in57644410831555
HER2-positive66244410834580118156178220261290306330347382418
breast11114441083396399133161186
cancer.132744410833267108142178201212
N1570444108346
Engl164644410833373115132
J1808444108325
Med.186344410835693135149
2011;365(14):1273-1283.34045410833468100128136171205239257289320337349379409442476498528558592626638
13.3404640085366883
Perez4374641083356990124153
EA,6044641083337690
Romond70846410833574132170209248
EH,9704641083327689
Suman107346410833370128160198
VJ,12854641083365769
et136846410833456
al.14384641083324860
Trastuzumab15124641083335083110133171200238296329368
plus18944641083385492118
adjuvant3404741083327085122154187225246
chemotherapy59847410833169103161199220258292313346384415
for10264741083185577
human111547410833774132164201
epidermal13294741083337287126160181239271286
growth16284741083375895145170207
factor18484741083185183107143164
receptor3404841083215587121160182219241
2-positive6004841083345595133160175197213245280
breast8994841083386094126152176
cancer:109448410833164102134168189203
planned13164841083395587125163198237
joint15724841083155369107128
analysis171948410833270103118150177192218
of195648410833756
overall34049410833768101122154169183
survival5354941083266283116132163195210
from7574941083184076133
NSABP90249410834476115150185
B-3110994941083355789119
and123049410833168106
NCCTG134949410834383121155197
N9831.155849410834477111145175183
J1754494108323
Clin17894941083405469106
Oncol1907494108346842140741083316884
Off2239741083476887
J234274108324
Am23817410834199
Soc24957410833371104
Clin2614741083405570108
Oncol.27377410834786118155171184
2014;32(33):3744-3752.29367410833468100131143178211228262295312324359391421458481514546579612624
14.2140840085366984
Gianni2243841083445991129167182
L,24448410833145
Eiermann2508841083324782103162194232270
W,27978410835767
Semiglazov28838410833267125140179194226256293325
V,32278410833644
et32908410833456
al.3365841083324760
Neoadjuvant34448410834580118151191206243276309347369
chemotherapy21409410833272109169209233273309332367408440
with2605941083526993133
trastuzumab2763941083224580108132172203243303337378
followed316694108319597692132185221263
by34549410833972
adjuvant3551941083337490130164199239261
trastuzumab21401041083224477104128166196235294327366
versus25271041083326789117154181
neoadjuvant272910410833874113146186202240273307345367
chemotherapy311710410833270106165203226265300322355395427
alone,35651041083324886125161173
in375910410831553
patients21401141083397395111147185208236
with23971141083516790129
HER2-positive254811410834478114151172213252280295318334367402
locally29711141083155488121137153185
advanced317711410833372106140178211246286
breast34841141083396296129156180
cancer36851141083326510421401241083326688
(the22491241083194180116
NOAH238612410834695136181
trial):2588124108323456194110129142
a2751124108332
randomised28051241083215593133173232248275311351
controlled317712410833270109132154192208224260300
superiority349812410832765105142163180219241257280315
trial2140134108322435991106
with22591341083516689127
a2399134108332
parallel24441341083387192125141156191206
HER2-negative266313410834477113149169208243282315336352384418
cohort.309413410833268107145167191205
Lancet331213410833165103135168191
Lond351613410833168107146
Engl.367513410833370109125137
2010;375(9712):377-384.214014410833468100131144179211244262294327360390408419455487521540572607643655
15.21401540085366883
Swain223715410833282115130168
SM,241915410833387101
Baselga25341541083356895130145184216
J,276415410832537
Kim281515410833551109
SB,29381541083326780
et303215410833456
al.31021541083324860
Pertuzumab,31771541083356889114152181220277310349361
Trastuzumab,35521541083335083109133170200238214016410835790129141
and229416410833270109
Docetaxel241716410834583116150172205237270286
in271616410831553
HER2-Positive278216410834478113149169206243269284307322355389
Metastatic318416410835590112145171194227249264296
Breast34941641083355690122149172
Cancer.3679164108340731112140174108331658696
N2252174108344
Engl231217410833270109125
J2452174108324
Med.249117410835590129143
2015;372(8):724-734.264917410833468100130141176208242259293311323356391423446477511546559
16.21401840085366985
Gianni22391841083445991129167182
L,243518410833245
Pienkowski24951841083354984122152190241268298314
T,282318410833342
Im287918410831573
YH,29661841083358193
et307418410833456
al.31441841083324760
Efficacy3219184108332506886118151183216
and344918410833270109
safety35731841083265978112135168
of375618410833756
neoadjuvant214019410833873111144183199236269302340361
pertuzumab25161941083397495120158187226283316355
and288619410833169108
trastuzumab30091941083224376103126164193231289322361
in338419410831553
women345119410835189147182220
with36861941083506688127
locally21402041083155284116131146177
advanced,233020410833169102134171203236275287
inflammatory,2629204108315526986117174231263284321342375385
or302620410833758
early30962041083346586101133
HER2-positive324120410834376111146166205243269284306321353386
breast36402041083385992124150172
cancer214021410833164102134168189
(NeoSphere):23452141083186398137169208246281302337354366
a2726214108332
randomised27742141083205391130169227242268303343
multicentre,313221410835795110133148180214252273295329341
open-label,348821410833877113151173190222261297312325
phase214022410833977109136171
22326224108335
trial.2376224108321435991106119
Lancet251022410833165103135169191
Oncol.271622410834786118155171184
2012;13(1):25-32.291522410833469100130143173203221252267279314349371403436448
17.21402340085356674
von222623410833168105
Minckwitz234323410835368105136165217232253283
G,263823410834356
Procter27062341083345490122145178198
M,291623410835467
de299423410833872
Azambuja307823410834070102159197234248279
E,336923410833245
et342623410833355
al.34932341083314558
Adjuvant35632341083407792128160192229249
Pertuzumab21402441083356990114152182220278310349
and250624410833270109
Trastuzumab26312441083335083110133171200238296328368
in301524410831553
Early30842441083336687103135
HER2-Positive323524410834477113148169206242269284306322354389
Breast36402441083355791123149172
Cancer.214025410834073111143177198208
N2364254108344
Engl242425410833270109124
J2564254108324
Med.260325410835490129142
2017;377(2):122-131.276125410833468100129139174206240257291309320350380415435466496527536
18.21402640085366985
Verma22462641083366890148180
S,244726410833245
Miles25122641083547085120147
D,267926410834556
Gianni27552641083445991129167182
L,295826410833145
et302326410833456
al.30992641083324760
Trastuzumab31792641083335083110133171200238296329368
Emtansine356726410833390112145183209224214027410833873
for22272741083185677
HER2-Positive231927410834477113148169205242269284306321354388
Advanced272227410834179112144182215248288
Breast30242741083365791123149173
Cancer.321127410834073111143177198208
N3433274108345
Engl349227410833371110125
J3632274108324
Med.367027410835590129142
2012;367(19):1783-1791.214028410833468100130142177212245261293323341353383412445479501532561595627636
19.21402940085366881
von223429410833169107
Minckwitz235329410835469107139168221236258289
G,265429410834457
Huang272429410834381113150189
CS,29252941083407486
Mano302429410835486123161
MS,31982941083548799
et331029410833355
al.33782941083324759
Trastuzumab34502941083324982108131168197235292324363
Emtansine214030410833390111144182208223260295
for24483041083185677
Residual25383041083357097111150187219235
Invasive27853041083155384117143158190224
HER2-Positive302230410834477112148168205241268283305320352386
Breast34213041083365791122149172
Cancer.360630410833972110142175196207
N2140314108345
Engl220031410833370109125
J2340314108324
Med.238031410835489129142
2019;380(7):617-628.253731410833468100130143178212248267302321333369399428447484518551565
20.21403240085377490
Chan225232410834180114153
A,242732410834257
Delaloge250532410834784100134150189230267
S,279332410833447
Holmes286232410834585101161197225
FA,31093241083337388
et321832410833558
al.32983241083334962
Neratinib338232410834682105139162178217233273
after36773241083335379114136
trastuzumab-based21403341083224376103126164193231289321361384424457484519558
adjuvant27153341083327186124156189227249
therapy29813341083216095116149188219
in321733410831553
patients32873341083387193108143181203230
with35343341083516689127
HER2-positive36783341083447711221403441083345595133160175197213245279
breast24363441083396195127153176
cancer262934410833164102134168189
(ExteNET):28353441083195284109142188221256278290
a3142344108332
multicentre,319034410835895111133148180214252274295329341
randomised,35483441083215492131169227242214035410832661101113
double-blind,226935410833876114154170204228268283298336375388
placebo-controlled,26733541083385487119152192231254287324363384406443459474509548561
phase325035410833977109136171
33437354108334
trial.3487354108321435890106119
Lancet362235410833164102135168191
Oncol.214036410834786118155171184
2016;17(3):367-377.233936410833468100131143173203219253270282317352384403435467502508
21.21403740085367082
Geyer223937410834479111145166
CE,24223741083407386
Forster25253741083337092119142176197
J,273937410832436
Lindquist27923741083324785124163201216242265
D,307437410834657
et314837410833456
al.32213741083324760
Lapatinib329837410833265104137159174212227266
plus35813741083395593119
Capecitabine371737410834073214038410833873105120142175213228266300
for24533841083185576
HER2-Positive254238410834376111146166202238265279301316348382
Advanced293738410834078110142180212245284
Breast32333841083355690121147170
Cancer.341538410834072110141175195205
N3633384108344
Engl369038410833269108123
J2140394108324
Med.217939410835590130143
2006;355(26):2733-2743.233739410833468104140152187220253271304338356368403436470503525556589620652665
22.21404040085367288
Cortés22434041083407798123157184
J,244240410832436
Kim249340410833451109
SB,26164041083336881
Chung271140410834078116154193
WP,29194041083579398
et303240410833456
al.31034041083324760
Trastuzumab31784041083324982109132170199238296328367
Deruxtecan356040410834581102140171196229214041410833164102
versus22554141083326687114151177
Trastuzumab24464141083324982109132170199237295327366
Emtansine282541410833390112145183209224261296
for31344141083195678
Breast32254141083355690122149172
Cancer.341041410834072110143176197208
N3631414108344
Engl368841410833371110125
J2140424108324
Med.217942410835590130143
2022;386(12):1143-1154.233742410833468101136148183218253272304334351363393421452484506537565595630643
23.21404340085367287
Kim224443410833551109
HJ,23694341083446982
Kim246743410833551109
S,259243410833245
Freedman26534341083335387122162219252290
RA,29594341083357892
et306843410833456
al.31404341083324760
The321643410833372107
impact334043410831472111144176200
of355743410833756
young362943410833169107145184
age214044410833271106
at226044410833254
diagnosis23284441083385385124162201227242268
(age26104441083195089124
<40274844410834273109
years)28714441083316597119146163
on304844410833776
prognosis31384441083396198137175214240255281
varies34344441083316485101136162
by361144410833870
breast3695444108339609421404541083325881
cancer223645410833164102134168189
subtype:244045410832663102124158198233246
A2700454108341
U.S.27564541083445589102
SEER28734541083326497133
database30204541083387092125164197224259
analysis.329345410833270102118149177191217231
Breast35394541083355690122149172
Off37254541083476887
J2140464108324
Eur21794641083337091
Soc228546410833371104
Mastology.240446410835487113137174189228267299309
2021;61:77-83.272946410833468101132140176206215248283301337371384
24.21404740085367186
Tolaney22404741083336782115153188219
SM,247347410833286100
Guo258647410834482120
H,271947410834557
Pernas27904741083356890128160187
S,299047410833346
et304947410833456
al.31184741083324860
Seven-Year319247410833267100134172194227258290311
Follow-Up35164741083337086101139190213258297
Analysis214048410834179111126158185199225
of237848410833756
Adjuvant24474841083417994132164197235256
Paclitaxel27164841083356698114128151183215248264
and299348410833169108
Trastuzumab31144841083324982109132169198236294326365
Trial3492484108332506597112
for36174841083185677
Node-Negative,37074841083448221404941083387396143178217249271286319353365
Human252049410834582140172210
Epidermal27464941083327187126160182240272288
Growth304949410834465103154178216
Factor32814941083326194118155176
Receptor347249410833671103137176198235257
2–374449410833469
Positive3940741083357299113136151184218
Breast4173741083365791123149173
Cancer.43617410834073111143177198208
J458574108324
Clin4624741083405570108
Oncol.47477410834786118155171184
2019;37(22):1868-1875.49467410833468100130143178210227261295313325355386421457479510541574607619
25.3940840085367388
Cortazar4048841083407799124157187221242
P,43118410833539
Zhang43718410833876109147186
L,45788410833145
Untch46448410834482104135173
M,48378410835569
et49268410833457
al.5004841083324760
Pathological5085841083356789128166182221260276308341357
complete546284108332691273940941083405793117153
response4117941083225786127167208235272
and44149410833372113
long-term4552941083155596137160184219242303
clinical4880941083324864104120154189205
benefit51109410834077117154172190214
in53489410831555
breast5428941083406398132160185
cancer:394010410833266105138172194209
the41701041083226197
CTNeoBC428910410834077124160200238279
pooled459010410833979119135171212
analysis.482310410833272105121153181197224238
Lancet508210410833266105139173196
Lond530010410833270109150
Engl.547110410833372112128141
2014;384(9938):164-172.394011410833468100131143178212249268301336369403421433463494531554584614648661
26.39401240085377490
Petrelli40521241083367194116152168184200
F,427312410833340
Coinu43341241083417996135174
A,452912410834257
Lonati460812410833270110144166183
V,481212410833746
et488012410833458
al.49591241083334962
Neoadjuvant504312410834682122156197213252286320359382
dose-544612410833979106143167
-dense39401341083216297136162198
chemotherapy415813410833270105164203225263299320353393425
for46031341083195779
locally47021341083155487120136151183
advanced490613410833271104137176208242282
breast52091341083396195127154178
cancer:540713410833265103136170191205
a3940144108333
meta-analysis399614410835995119153177211250284301334362378406
of442414410833959
published450614410834080121138154181221257298
studies.48271441083275291132148185213227
Anticancer507714410834282105121155189229263298320
Drugs.542014410834770110150178192
2016;27(7):702-708.394015410833468100131143178211228262282294327360393414445478513527
27.39401640085367180
Gray40341641083446598129
R,417716410833650
Bradley42411641083355790129144179210
R,446516410833650
Braybrooke45291641083355790121160182219258288323
J,486616410832436
et491616410833456
al.49871641083314760
Increasing50611641083155385106140172199213251290
the53661641083215994
dose547516410833876103138
intensity39401741083155274107145172186209242
of419517410833756
chemotherapy426417410833169104162200222260295316349388419
by469617410833869
more477817410835796117151
frequent49421741083184074113151186224245
administration520017410833271128143181196222245266299321336374412
or394018410833759
sequential401218410832661101138173211233248280295
scheduling:43211841083265896131170208223238276315327
a4662184108331
patient-level47071841083387193108143181203222239273306340356
meta-analysis507618410835792114147170202240272288319346361387
of547618410833857
37554618410833466
298394019410833468103
women405619410835188146181219
with42891941083506688126
early44281941083346687103134
breast45751941083396195126153176
cancer476419410833164102134168189
in496619410831552
26503119410833468
randomised51121941083215492131169227242268303342
trials.5467194108322435991106132146
The394020410833372107
Lancet.406220410833265103135169191204
2019;393(10179):1440-1452.428220410833468100130143178211244262294325357386420438449479510547583607638669702735747
28.39402140085367389
Del40472141083458198
Mastro416221410835588115139161199
L,437921410833146
Poggio444321410833572112152168207
F,466721410833339
Blondeaux47242141083365291130170205238276308
E,505021410833346
et511421410833457
al.51892141083324861
Fluorouracil52682141083324886125147185224246279312328344
and394022410833271110
dose-dense407022410833877105140164205241280307343
adjuvant44332241083317187125159192231253
chemotherapy470722410833169105164203225264300322356395427
in515522410831453
patients52282241083397295111146185207235
with54842241083506690128
early-stage39402341083346688104136159186210243283318
breast42722341083396195128155178
cancer446423410833165103136170192
(GIM2):46702341083186278133168186199
end-of-study488323410833472112135175195216243267305345377
results52742341083215582120136159187
from54752341083184179137
a3940244108332
randomised,39862441083205492131170228244270306346359
phase435924410833877110137172
34545244108334
trial.4593244108322446092108121
Lancet472824410833265104136170193
Oncol.493524410834786118156172185
2022;23(12):15711582.513424410833469102137150185220239271301320332362393426459394025410833465100134147
29.39402640085367285
Ramshorst404226410833568126152190228250277300
MS435926410835487
van,446226410833265103116
Voort459426410833571110132156
A4767264108341
van482426410833164102
der,49432641083387394104
Werkhoven506326410835790112142181220252286324
ED540326410833378
van,549826410833164102115
et394027410833455
al.40082741083314659
Neoadjuvant407927410834478116149187202239271303341362
chemotherapy445327410833168102159197218256290311343382412
with48782741083506587124
or501527410833658
without50852741083506587124162199221
anthracyclines5319274108331699012714818021224427539402841083153068103130
in408728410831452
the41572841083215994
presence42692841083386094121156194226260
of454628410833757
dual462028410833876108123
HER2476128410834477112148
blockade49262841083395593126156189228263
for52062841083195678
HER2-positive53012841083447811314916920924827528939402941083223769104
breast40602941083396094126153176
cancer425229410833264102135168190
(TRAIN-2):44582941083185491134149195217248266278
a4752294108332
multicentre,480129410835795110132148180213251273294328340
open-label,515829410833776112150173189221260296312324
randomised,54982941083215492394030410833876135150176211250263
phase421830410833977110136171
34405304108334
trial.4454304108322435991106119
Lancet458830410833265103135169191
Oncol.479530410834785118154170183
2018;19(12):1630-1640.499430410833468100131143173203222254284302314344375408443467498529565601614
30.39403140085367287
Chan404231410834078110148
A,420431410834155
Moy427331410835593124
B,441131410833648
Mansi447331410835587125152166
J,465331410832537
et470431410833456
al.47743141083324760
Final48483141083324785117133
Efficacy4995314108332506886118151183216
Results52253141083367198135150173200
of543931410833857
Neratinib5510314108345803940324108321547691129144184
in414432410831553
HER2-positive421832410834477113149169210249276291313329361396
Hormone463432410834583105164202241276
Receptor-positive493132410833570103137176199236258277318357384399421437469504
Early-54553241083336688103135157
-stage39403341083214872105144179
Breast41403341083365792124151174
Cancer433533410834073111144178199
From45553341083325290149
the47243341083226196
Phase484133410833573105132168
III50293341083153146
ExteNET50963341083326590124170203239
Trial.5355334108333516699114127
Clin55033341083405671109
Breast39403441083355791123149172
Cancer.412834410834072110143176198208
2021;21(1):80-91.e7.435134410833468101133141176207222254269280315351374409441451486518524
31.39403540085366981
Baselga40363541083356895130145184217
J,426735410832436
Cortés43183541083407798123157184
J,451635410832436
Kim456735410833551109
SB,46903541083336880
et478535410833456
al.48553541083324861
Pertuzumab49303541083356990114152182220278310349
plus52943541083385492118
trastuzumab54273541083214376102125163394036410832866124157196
plus41513641083385492118
docetaxel428436410833876109143165198229263279
for45783641083185677
metastatic467036410835793115148174197230252267299
breast49843641083396094126153176
cancer.517536410833164102134168189199
N5389364108345
Engl544936410833270109124
J5588364108324
Med.394037410835490129142
2012;366(2):109-119.409837410833468100129142177211247266300318330359391426450480508538549
32.39403840085367186
Bendell404438410833571109148183198213
JC,42743841083246578
Domchek436938410834684143175213248278
SM,466438410833387101
Burstein47823841083357394121144178193231
HJ,50303841083447082
et512938410833456
al.52023841083324760
Central527938410834074112133155188203
nervous54993841083387394394039410833270109135
system40963941083265987110144203
metastases432039410835793116149176199232259295322
in466339410831553
women473739410835189148183222
who498039410835190128
receive51293941083215689123138171206
trastuzumab-based53563941083214377104127165195234394040410835790129153193226253288328
therapy42884041083226095117150189221
for45294041083195678
metastatic462840410835792115148174198231252268300
breast49484041083396195127154177
carcinoma.51464041083316485116132170208267299312
Cancer.5479404108340731113940414108331658696
2003;97(12):2972-2977.405241410833468104137149184217233265295313325360394427461482513547580614620
33.39404240085367185
Brufsky40384241083355695114141171205
AM,425642410834096109
Mayer437842410835486117151172
M,456342410835468
Rugo464442410833572111149
HS,48064241083447689
et490842410833356
al.49764241083324760
Central504942410834073111133154187202
nervous52644241083377293128165203229
system55064241083265885394043410832256114
metastases407543410835893115149175199232259294321
in441743410831453
patients44904341083397395110145183205233
with47444341083516789128
HER2-positive489243410834578114150171211250277292315330363398
metastatic531043410835893116149176199232254270302
breast39404441083396094126153176
cancer:413044410833164102134168189203
incidence,43474441083155385100139174212244278290
treatment,46514441083214377109131189224262283297
and496244410833270109
survival50854441083266384119135167200216
in531544410831552
patients53824441083387193108143181203230
from39404541083184078136
registHER.40924541083215595110136159204237272287
Clin43954541083405570108
Cancer451945410834073111143177198
Res47334541083367197
Off48474541083476786
J4950454108324
Am499045410834199
Assoc51054541083416996134167
Cancer528845410834073111143176198
Res.55024541083357097111
2011;17(14):4834-4843.394046410833468100128136166195212243275292304338374408444467503539576608621
34.39404740085367388
Murthy404347410835492113138176207
RK,42644741083367286
Loi43654741083316984
S,446347410833346
Okines45234741083477894132167194
A,473247410834155
et480147410833456
al.48724741083324760
Tucatinib,49464741083336699131153169206221261273
Trastuzumab,52334741083335083109133171200238296328367380
and394048410833270109
Capecitabine406848410834073112148181196218251290306344379
for44664841083195678
HER2-Positive456348410834478113149169206243269284307322355389
Metastatic497148410835590112145172195228249265297
Breast52874841083365791123149173
Cancer.5479484108340731113940494108331658696
N4052494108344
Engl411249410833270109125
J4252494108324
Med.429149410835590129143
2020;382(7):597-609.444949410833468101135148183217251268303322334370402435453491526561572
www.onkologiecs.cz510734703612214506797298921058119713571428159217611830197921162237230024322566
Onkologie510702603772193995707418281003118112681428